| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Body Worn Devices | | | | | 80.5 | | | |
| Medical Biotelemetry, Diabetes | | | | | 43.4 | | | |
| Medical Biotelemetry, Other Medical | | | | | 10.1 | | | |
| Legacy OEM | | | | | 11.4 | | | |
| Total revenues | 125.2 | 102.8 | 113.5 | 113.9 | 87.0 | 69.0 | 68.5 | 67.1 |
| Revenue growth | 21.8% | -9.4% | -0.4% | 31.0% | 26.1% | 0.7% | 2.1% | 26.7% |
| Cost of goods sold | 93.8 | 76.6 | 82.5 | 77.7 | 61.7 | 52.3 | 49.8 | 49.0 |
| Gross profit | 31.4 | 26.2 | 31.0 | 36.2 | 25.3 | 16.7 | 18.8 | 18.1 |
| Gross margin | 25.1% | 25.5% | 27.3% | 31.8% | 29.1% | 24.2% | 27.4% | 27.0% |
| Selling, general and administrative [+] | 24.9 | 21.7 | 33.0 | 27.9 | 17.2 | 13.9 | 10.7 | 9.5 |
| Sales and marketing | 8.3 | 6.7 | | | 8.3 | 4.7 | 3.7 | 3.5 |
| General and administrative | 16.6 | 15.0 | | | 9.0 | 9.2 | 7.0 | 5.9 |
| Research and development | 5.3 | 5.2 | | | 4.5 | 4.7 | 4.3 | 4.3 |
| Equity in earnings | | | | | | | | |
| Other operating expenses | 0.7 | 0.7 | -0.2 | -0.5 | -0.1 | -0.4 | -0.2 | -0.2 |
| EBITDA [+] | 6.0 | 3.2 | 1.5 | 11.8 | 5.9 | 0.6 | 5.7 | 6.7 |
| EBITDA growth | 87.7% | 118.3% | -87.5% | 100.8% | 843.3% | -89.1% | -15.1% | 327.0% |
| EBITDA margin | 4.8% | 3.1% | 1.3% | 10.3% | 6.7% | 0.9% | 8.3% | 10.0% |
| Depreciation | 3.5 | 3.2 | 2.8 | 2.9 | 2.0 | 2.0 | 1.8 | 2.2 |
| EBITA | 2.5 | 0.0 | -1.3 | 8.9 | 3.9 | -1.4 | 3.9 | 4.5 |
| EBITA margin | 2.0% | 0.0% | -1.2% | 7.8% | 4.5% | -2.1% | 5.7% | 6.7% |
| Amortization of intangibles | 2.0 | 1.5 | 0.5 | | 0.2 | | | |
| EBIT [+] | 0.5 | -1.4 | -1.8 | 8.9 | 3.7 | -1.4 | 3.9 | 4.5 |
| EBIT growth | -134.5% | -21.9% | -120.4% | 138.3% | -362.3% | -136.1% | -12.9% | -612.8% |
| EBIT margin | 0.4% | -1.4% | -1.6% | 7.8% | 4.3% | -2.1% | 5.7% | 6.7% |
| Non-recurring items | | 1.7 | 0.2 | 0.5 | 0.1 | 0.5 | 0.2 | 0.2 |
| Interest expense, net [+] | 0.0 | -0.3 | | | 0.7 | 0.6 | 0.4 | 0.5 |
| Interest expense | 0.0 | | | | 0.7 | 0.6 | 0.4 | 0.5 |
| Interest income | | 0.3 | | | | | | |
| Other income (expense), net [+] | -0.4 | 0.3 | 0.2 | -1.1 | -0.4 | -0.6 | -0.3 | 0.0 |
| Other | | | | | -0.4 | -0.6 | -0.3 | 0.0 |
| Pre-tax income | 0.1 | -2.4 | -1.9 | 7.2 | 2.5 | -3.1 | 3.1 | 3.8 |
| Income taxes | 0.1 | 0.1 | 0.2 | 0.5 | 0.0 | 0.2 | 0.0 | 0.4 |
| Tax rate | 190.1% | | | 6.7% | 0.3% | | 0.6% | 11.2% |
| Minority interest | 0.0 | 0.0 | | | -0.9 | -0.2 | -0.1 | |
| Earnings from continuing ops | -0.1 | -2.5 | -3.8 | 5.5 | 5.7 | -3.2 | 6.3 | 6.8 |
| Earnings from discontinued ops | | | -0.6 | -1.2 | -1.2 | -1.8 | -1.0 | -1.1 |
| Net income | -0.1 | -2.5 | -3.8 | 5.5 | 4.5 | -4.9 | 5.3 | 5.6 |
| Net margin | -0.1% | -2.5% | -3.3% | 4.9% | 5.2% | -7.2% | 7.7% | 8.4% |
| |
| Basic EPS [+] | ($0.01) | ($0.28) | ($0.43) | $0.73 | $0.83 | ($0.49) | $1.06 | $1.17 |
| Growth | -95.9% | -34.3% | -159.1% | -12.0% | -269.8% | -146.0% | -9.2% | -391.3% |
| Diluted EPS [+] | ($0.01) | ($0.28) | ($0.43) | $0.64 | $0.78 | ($0.49) | $1.01 | $1.12 |
| Growth | -95.9% | -34.3% | -167.2% | -17.3% | -259.2% | -148.6% | -10.4% | -379.4% |
| |
| Shares outstanding (basic) [+] | 9.1 | 8.9 | 8.7 | 7.6 | 6.9 | 6.5 | 5.9 | 5.8 |
| Growth | 2.1% | 1.7% | 15.1% | 10.9% | 5.5% | 10.0% | 2.0% | 1.6% |
| Shares outstanding (diluted) [+] | 9.1 | 8.9 | 8.7 | 8.6 | 7.3 | 6.5 | 6.2 | 6.0 |
| Growth | 2.1% | 1.7% | 1.4% | 18.1% | 12.5% | 4.1% | 3.4% | 5.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |